# US 2023/0057418 A1 · The Kinase NEK10 and Its Use in Treating and Diagnosing Bronchiectasis and Other Respiratory Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057418 A1
- Document ID: US20230057418A1
- Status: Published application
- Kind: A1
- Application number: 17/793,142
- Filed: 2021-01-19
- Published: 2023-02-23
- Earliest claimed: 2020-01-16
- Assignees: The General Hospital Corporation; Whitehead Institute for Biomedical Research
- Applicants: The General Hospital Corporation; Whitehead Institute for Biomedical Research
- Inventors: Raghu R. Chivukula; David M. Sabatini
- Web page: https://patentgrep.com/patent/US20230057418A1

## CPC

- A61K 38/45: Transferases (2)
- A61P 11/00: Drugs for disorders of the respiratory system
- G01N 33/573: for enzymes or isoenzymes
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Y 207/11001: Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
- G01N 2800/12: Pulmonary diseases
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Y: ENZYMES

## Abstract

Aspects of the present disclosure provide compositions comprising NEK10 for example, wild-type NEK10 or a hyper-active NEK10 mutant such as NEK10S684D, and methods of using such for treating a respiratory disorder such as bronchiectasis.

## Claims

### Claim 1

A method of treating a respiratory disorder, the method comprising administering to a subject in need thereof an effective amount of NEK10.

### Claim 2 (depends on 1)

The method of claim 1, wherein NEK10 is wild-type NEK10 comprising SEQ ID NO: 1 or a fragment thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein NEK10 is a NEK10 mutant comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 1.

### Claim 4 (depends on 3)

The method of claim 3, wherein the amino acid sequence is at least 90% identical to SEQ ID NO: 1.

### Claim 5 (depends on 3)

The method of claim 3, wherein the amino acid sequence is at least 95% identical to SEQ ID NO: 1.

### Claim 6 (depends on 3)

The method of claim 3, wherein the amino acid sequence comprises an amino acid substitution at position S684.

### Claim 7 (depends on 6)

The method of claim 6, wherein the amino acid substitution at position S684 is S684D.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the respiratory disorder is selected from the group consisting of asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), emphysema, primary ciliary dyskinsesia (PCD), and immunodeficiency.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the subject is a human patient.

### Claim 10

A method of diagnosing a subject as having a respiratory disorder, the method comprising:
providing a sample from the subject, and
detecting a mutation in NEK10 in the sample, wherein presence of the mutation in NEK10 indicates that the subject has a respiratory disorder, or
detecting a level of NEK10 in the sample and comparing the level of NEK10 in the sample to a reference level, wherein presence of a level of NEK10 in the sample that is below the reference level indicates that the subject has a respiratory disorder.

### Claim 11 (depends on 10)

The method of claim 10, wherein the mutation in NEK10 is selected from the group consisting of NM_152534:c.1230+5G>C (insertion of VTALLLK), NM_152534:c.1869dupT (H624Sfs*4), NM_152534:c.2243C>T (P748L), NM_152534:c.1373+1G>T (C437Tfs*9), and NM_152534:c.2317C>T (R773C).

### Claim 12 (depends on 10, 11)

The method of claim 10 or claim 11, further comprising treating the subject with an effective amount of a therapy selected from the group consisting of NEK10, a bronchodilator, an antibiotic, an expectorant, oxygen therapy, chest physiotherapy, an anti-inflammatory agent, and a mucolytic.

### Claim 13 (depends on 12)

The method of claim 12, wherein NEK10 is wild-type NEK10 comprising SEQ ID NO: 1 or a fragment thereof.

### Claim 14 (depends on 12)

The method of claim 12, wherein NEK10 is a NEK10 mutant comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 1.

### Claim 15 (depends on 14)

The method of claim 14, wherein the amino acid sequence is at least 90% identical to SEQ ID NO: 1.

### Claim 16 (depends on 14)

The method of claim 14, wherein the amino acid sequence is at least 95% identical to SEQ ID NO: 1.

### Claim 17 (depends on 14)

The method of claim 14, wherein the amino acid sequence comprises an amino acid substitution at position S684.

### Claim 18 (depends on 17)

The method of claim 17, wherein the amino acid substitution at position S684 is S684D.

### Claim 19 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 10-18, wherein the sample is a blood sample or a tissue sample.

### Claim 20 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 10-19, wherein the sample is obtained from a subject having or at risk for having a respiratory disorder.

### Claim 21 (depends on 20)

The method of claim 20, wherein the respiratory disorder is selected from the group consisting of asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), emphysema, primary ciliary dyskinsesia (PCD), and immunodeficiency.

### Claim 22 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 10-21, wherein the subject is a human patient.

### Claim 23

A method of increasing mucociliary transport (MCT) in an airway epithelium, the method comprising administering an effective amount of NEK10 to the airway epithelium.

### Claim 24 (depends on 23)

The method of claim 23, wherein NEK10 is wild-type NEK10 comprising SEQ ID NO: 1 or a fragment thereof.

### Claim 25 (depends on 23)

The method of claim 23, wherein NEK10 is a NEK10 mutant comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 1.

### Claim 26 (depends on 25)

The method of claim 25, wherein the amino acid sequence is at least 90% identical to SEQ ID NO: 1.

### Claim 27 (depends on 25)

The method of claim 25, wherein the amino acid sequence is at least 95% identical to SEQ ID NO: 1.

### Claim 28 (depends on 25)

The method of claim 25, wherein the amino acid sequence comprises an amino acid substitution at position S684.

### Claim 29 (depends on 28)

The method of claim 28, wherein the amino acid substitution at position S684 is S684D.

### Claim 30 (depends on 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 23-29, wherein the airway epithelium is in vitro or in vivo.
